⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VNDA News
Vanda Pharmaceuticals Inc.
Vendavo Named a Leader in the Gartner® Magic Quadrant™ for B2B Pricing & Rebate Optimization Software
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
prnewswire.com
VNDA
Polycythemia Vera Market Set for Transformation: Key 9 Companies Expected to Enter by 2036 | DelveInsight
globenewswire.com
TSEM
TAK
MRK
IONS
SLN
INCY
JNJ
VNDA
Vanda Pharmaceuticals, Inc. Investigated by the Portnoy Law Firm
globenewswire.com
VNDA
Vedanta Biosciences Showcases Innovative Work on its Microbiome-based Therapeutics at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 Global Congress
businesswire.com
VNDA
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
prnewswire.com
VNDA
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
prnewswire.com
VNDA
Form 8-K
sec.gov
VNDA
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
businesswire.com
VNDA